Theriva Biologics, Inc.
NYSE · Healthcare · Pharmaceutical Preparations · Rockville, MD
TOVX chart
What traders are saying about $TOVX
Latest postsTheriva Biologics, Inc. news
- Theriva Biologics, Inc. (TOVX) Seasonal returns chart
Yahoo Finance UK ·
- What Does Tiny Market Value Mean: Theriva Biologics (NYSEAMERICAN:TOVX), 22nd Century Group (NASDAQ:XXII), Acumen Pharmaceuticals (NASDAQ:ABOS), Hain Celestial (NASDAQ:HAIN) and Senti Biosciences (NASDAQ:SNTI)?
kalkine.ca ·
- Which Penny Stock Looks Riskiest: Acumen Pharmaceuticals (NASDAQ:ABOS), Senti Biosciences (NASDAQ:SNTI), Theriva Biologics (NYSEAMERICAN:TOVX), Context Therapeutics (NASDAQ:CNTX) or Hain Celestial (NASDAQ:HAIN)?
kalkine.ca ·
- Graft-Versus Host Disease Market Size, Share, Trends,
openPR.com ·
- Theriva™ Biologics Announces Sale of SYN-004 (ribaxamase) and Related Antibiotic-Degrading Enzyme Portfolio to Biossil Labs Inc.
Yahoo Finance ·
- Theriva™ Biologics Announces Publication of the Results from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer Published in Nature Medicine
Yahoo Finance ·
- Theriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results
Yahoo Finance ·
- Theriva™ Biologics Announces First Patient Dosed in VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Yahoo Finance ·
- Theriva™ Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Yahoo Finance ·
- Theriva™ Biologics Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer Published in Clinical Cancer Research
Yahoo Finance ·
- Theriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results
Yahoo Finance ·
- Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting
Yahoo Finance ·
Theriva Biologics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Net income | -$23.7M | -$25.7M | -$18.3M | -$19.7M |
| Diluted EPS | $-2.08 | $-19.03 | $-28.48 | $-1.31 |
| Total assets (year end) | $38.2M | $35.4M | $55.2M | $71.9M |
| Cash and equivalents (year end) | $13.1M | $11.6M | $23.2M | $41.8M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Theriva Biologics, Inc.
- Ticker
- TOVX (NYSE)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Rockville, MD
- Incorporated in
- NV
- Fiscal year end
- December 31
- SEC CIK
- 894158
- Former names
- Synthetic Biologics, Inc., ADEONA PHARMACEUTICALS, INC., PIPEX PHARMACEUTICALS, INC.
Frequently asked questions
What exchange is Theriva Biologics, Inc. listed on?
Theriva Biologics, Inc. trades on the NYSE under the ticker symbol TOVX.
What industry is Theriva Biologics, Inc. in?
Theriva Biologics, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Theriva Biologics, Inc. headquartered?
Theriva Biologics, Inc.'s business address on file with the SEC is in Rockville, MD.
When does Theriva Biologics, Inc.'s fiscal year end?
Theriva Biologics, Inc.'s fiscal year ends on December 31.
How much revenue did Theriva Biologics, Inc. report?
Theriva Biologics, Inc. reported $0 in revenue for calendar year 2011, according to its SEC filings.